| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 110 | 2024 | 712 | 26.380 |
Why?
|
| Kidney Failure, Chronic | 63 | 2022 | 929 | 8.110 |
Why?
|
| Glomerular Filtration Rate | 46 | 2023 | 586 | 7.500 |
Why?
|
| Kidney Diseases | 25 | 2022 | 678 | 5.210 |
Why?
|
| Diabetes Mellitus, Type 2 | 27 | 2024 | 1415 | 4.780 |
Why?
|
| Renal Dialysis | 49 | 2024 | 901 | 4.720 |
Why?
|
| Cardiovascular Diseases | 49 | 2024 | 2213 | 4.670 |
Why?
|
| Diabetic Nephropathies | 18 | 2024 | 175 | 4.440 |
Why?
|
| Heart Failure | 17 | 2024 | 2331 | 2.890 |
Why?
|
| Kidney | 19 | 2024 | 2101 | 2.860 |
Why?
|
| Hypertension, Pulmonary | 6 | 2024 | 463 | 2.830 |
Why?
|
| Bariatric Surgery | 8 | 2021 | 122 | 2.710 |
Why?
|
| Angiotensin Receptor Antagonists | 10 | 2024 | 143 | 2.500 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 17 | 2022 | 824 | 2.490 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 11 | 2024 | 242 | 2.460 |
Why?
|
| Heart-Assist Devices | 6 | 2024 | 1047 | 2.300 |
Why?
|
| Acute Kidney Injury | 12 | 2022 | 758 | 2.170 |
Why?
|
| Cause of Death | 20 | 2024 | 780 | 2.130 |
Why?
|
| Nephrology | 7 | 2022 | 153 | 1.900 |
Why?
|
| Obesity | 20 | 2024 | 2888 | 1.880 |
Why?
|
| Antihypertensive Agents | 10 | 2024 | 432 | 1.830 |
Why?
|
| Weight Loss | 12 | 2021 | 626 | 1.820 |
Why?
|
| Creatinine | 15 | 2023 | 524 | 1.820 |
Why?
|
| Humans | 262 | 2024 | 270709 | 1.790 |
Why?
|
| Blood Pressure | 12 | 2021 | 1555 | 1.770 |
Why?
|
| Kidney Transplantation | 21 | 2023 | 750 | 1.720 |
Why?
|
| Hospitalization | 11 | 2021 | 2169 | 1.710 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 8 | 2024 | 28 | 1.670 |
Why?
|
| Registries | 19 | 2022 | 2208 | 1.620 |
Why?
|
| Body Mass Index | 20 | 2022 | 2225 | 1.540 |
Why?
|
| Hyperkalemia | 7 | 2024 | 79 | 1.520 |
Why?
|
| Hypoglycemic Agents | 14 | 2024 | 601 | 1.520 |
Why?
|
| United States | 50 | 2024 | 15817 | 1.430 |
Why?
|
| Randomized Controlled Trials as Topic | 36 | 2024 | 2657 | 1.390 |
Why?
|
| Renal Insufficiency | 4 | 2023 | 304 | 1.370 |
Why?
|
| Albuminuria | 9 | 2019 | 110 | 1.350 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 5 | 2024 | 74 | 1.340 |
Why?
|
| Risk Factors | 53 | 2024 | 17850 | 1.330 |
Why?
|
| Triglycerides | 10 | 2017 | 610 | 1.250 |
Why?
|
| Male | 135 | 2024 | 128479 | 1.250 |
Why?
|
| Renal Replacement Therapy | 8 | 2021 | 149 | 1.240 |
Why?
|
| Referral and Consultation | 7 | 2012 | 930 | 1.220 |
Why?
|
| Metabolic Syndrome | 6 | 2024 | 367 | 1.210 |
Why?
|
| Hypertension | 12 | 2022 | 1584 | 1.190 |
Why?
|
| Veterans | 7 | 2023 | 1739 | 1.190 |
Why?
|
| Aged | 94 | 2024 | 73601 | 1.180 |
Why?
|
| Middle Aged | 109 | 2024 | 90517 | 1.180 |
Why?
|
| Female | 130 | 2024 | 148873 | 1.120 |
Why?
|
| Obesity, Morbid | 4 | 2021 | 234 | 1.100 |
Why?
|
| Electronic Health Records | 9 | 2019 | 852 | 1.100 |
Why?
|
| Hospital Mortality | 7 | 2019 | 1233 | 1.090 |
Why?
|
| Proportional Hazards Models | 21 | 2021 | 5093 | 1.060 |
Why?
|
| Mortality | 6 | 2023 | 347 | 1.040 |
Why?
|
| Insulin Resistance | 7 | 2020 | 718 | 1.020 |
Why?
|
| Primary Prevention | 2 | 2019 | 233 | 1.020 |
Why?
|
| Proteinuria | 9 | 2020 | 152 | 1.010 |
Why?
|
| Chelating Agents | 4 | 2016 | 131 | 1.010 |
Why?
|
| Stroke Volume | 6 | 2023 | 550 | 0.980 |
Why?
|
| Ohio | 12 | 2017 | 116 | 0.970 |
Why?
|
| Risk Assessment | 26 | 2023 | 6765 | 0.970 |
Why?
|
| Aged, 80 and over | 42 | 2021 | 31113 | 0.970 |
Why?
|
| Disease Progression | 30 | 2024 | 6880 | 0.970 |
Why?
|
| Cholesterol | 9 | 2021 | 656 | 0.950 |
Why?
|
| Ventricular Function, Left | 5 | 2023 | 563 | 0.930 |
Why?
|
| Retrospective Studies | 40 | 2024 | 39968 | 0.930 |
Why?
|
| Defibrillators, Implantable | 3 | 2018 | 227 | 0.920 |
Why?
|
| Cohort Studies | 33 | 2023 | 9451 | 0.910 |
Why?
|
| Kidney Function Tests | 5 | 2022 | 198 | 0.910 |
Why?
|
| Phosphorus | 4 | 2014 | 68 | 0.900 |
Why?
|
| Phosphates | 3 | 2016 | 178 | 0.890 |
Why?
|
| Hyperphosphatemia | 2 | 2016 | 20 | 0.880 |
Why?
|
| Prevalence | 18 | 2024 | 3392 | 0.880 |
Why?
|
| Hip Fractures | 5 | 2020 | 85 | 0.870 |
Why?
|
| Nutrition Surveys | 5 | 2021 | 315 | 0.870 |
Why?
|
| Angioedema | 1 | 2023 | 22 | 0.860 |
Why?
|
| Echocardiography | 4 | 2023 | 1218 | 0.850 |
Why?
|
| Severity of Illness Index | 13 | 2019 | 4392 | 0.850 |
Why?
|
| Electrolytes | 1 | 2022 | 63 | 0.820 |
Why?
|
| Chronic Disease | 17 | 2014 | 1824 | 0.810 |
Why?
|
| Inflammation | 5 | 2020 | 2491 | 0.810 |
Why?
|
| Patient Navigation | 3 | 2017 | 33 | 0.790 |
Why?
|
| Cardiovascular System | 1 | 2023 | 142 | 0.790 |
Why?
|
| Renin-Angiotensin System | 5 | 2023 | 103 | 0.790 |
Why?
|
| Atrial Fibrillation | 6 | 2018 | 724 | 0.780 |
Why?
|
| Anemia | 6 | 2020 | 725 | 0.770 |
Why?
|
| Atherosclerosis | 4 | 2023 | 908 | 0.750 |
Why?
|
| Sevelamer | 3 | 2016 | 10 | 0.740 |
Why?
|
| Abdominal Fat | 1 | 2020 | 20 | 0.730 |
Why?
|
| Calcium Compounds | 2 | 2011 | 8 | 0.720 |
Why?
|
| Prosthesis Implantation | 2 | 2020 | 243 | 0.720 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2023 | 626 | 0.710 |
Why?
|
| Comorbidity | 13 | 2021 | 2393 | 0.700 |
Why?
|
| Polyamines | 2 | 2011 | 80 | 0.700 |
Why?
|
| Adult | 68 | 2024 | 82042 | 0.680 |
Why?
|
| Blood Volume | 1 | 2020 | 105 | 0.670 |
Why?
|
| Patient Care Management | 1 | 2020 | 92 | 0.660 |
Why?
|
| Chi-Square Distribution | 9 | 2016 | 1306 | 0.660 |
Why?
|
| Camellia | 1 | 2019 | 1 | 0.660 |
Why?
|
| Vitamin D | 3 | 2011 | 260 | 0.650 |
Why?
|
| Heart Diseases | 5 | 2024 | 722 | 0.630 |
Why?
|
| Glomerulonephritis, IGA | 2 | 2009 | 18 | 0.630 |
Why?
|
| Odds Ratio | 11 | 2021 | 2297 | 0.620 |
Why?
|
| Kidney Tubules | 1 | 2018 | 122 | 0.620 |
Why?
|
| Stroke | 9 | 2024 | 1060 | 0.610 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2021 | 139 | 0.610 |
Why?
|
| Acidosis | 1 | 2019 | 104 | 0.610 |
Why?
|
| Heart Ventricles | 1 | 2023 | 837 | 0.610 |
Why?
|
| Heart Transplantation | 2 | 2022 | 904 | 0.600 |
Why?
|
| Protons | 1 | 2021 | 480 | 0.600 |
Why?
|
| Immunologic Factors | 2 | 2020 | 669 | 0.600 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2022 | 288 | 0.580 |
Why?
|
| Sexual Dysfunction, Physiological | 4 | 2012 | 136 | 0.580 |
Why?
|
| Secondary Prevention | 1 | 2019 | 311 | 0.580 |
Why?
|
| Cardiac Resynchronization Therapy | 2 | 2018 | 30 | 0.580 |
Why?
|
| Health Records, Personal | 1 | 2017 | 21 | 0.580 |
Why?
|
| Cross-Sectional Studies | 15 | 2021 | 4494 | 0.580 |
Why?
|
| Biomarkers | 16 | 2020 | 5049 | 0.580 |
Why?
|
| Cholesterol, HDL | 2 | 2018 | 362 | 0.570 |
Why?
|
| Treatment Outcome | 35 | 2024 | 33847 | 0.570 |
Why?
|
| Overweight | 4 | 2019 | 480 | 0.560 |
Why?
|
| Fish Oils | 1 | 2017 | 89 | 0.560 |
Why?
|
| Hypernatremia | 1 | 2017 | 29 | 0.560 |
Why?
|
| Adiponectin | 3 | 2015 | 142 | 0.560 |
Why?
|
| Time Factors | 20 | 2020 | 12974 | 0.550 |
Why?
|
| Bicarbonates | 2 | 2019 | 108 | 0.550 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2017 | 83 | 0.540 |
Why?
|
| Follow-Up Studies | 19 | 2019 | 15274 | 0.540 |
Why?
|
| Hospitalists | 2 | 2008 | 58 | 0.530 |
Why?
|
| Arginine Vasopressin | 1 | 2016 | 66 | 0.530 |
Why?
|
| Adiposity | 5 | 2019 | 238 | 0.530 |
Why?
|
| Hyponatremia | 1 | 2017 | 86 | 0.530 |
Why?
|
| Age Factors | 13 | 2018 | 5436 | 0.520 |
Why?
|
| Fibroblast Growth Factors | 5 | 2016 | 258 | 0.520 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2021 | 444 | 0.510 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2019 | 198 | 0.510 |
Why?
|
| Contrast Media | 3 | 2018 | 1505 | 0.510 |
Why?
|
| Exercise Therapy | 2 | 2015 | 293 | 0.510 |
Why?
|
| Heart Valve Prosthesis | 1 | 2019 | 306 | 0.510 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2017 | 165 | 0.500 |
Why?
|
| Interleukin-1 | 1 | 2017 | 472 | 0.500 |
Why?
|
| Ischemic Attack, Transient | 1 | 2015 | 66 | 0.500 |
Why?
|
| Diet, Reducing | 1 | 2015 | 82 | 0.500 |
Why?
|
| Hypokalemia | 1 | 2015 | 61 | 0.500 |
Why?
|
| Patient Readmission | 1 | 2020 | 571 | 0.490 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2015 | 402 | 0.490 |
Why?
|
| Diabetes Mellitus | 7 | 2022 | 1042 | 0.490 |
Why?
|
| Prognosis | 22 | 2021 | 22528 | 0.490 |
Why?
|
| Electric Countershock | 1 | 2015 | 72 | 0.490 |
Why?
|
| Hyperlipidemias | 3 | 2014 | 220 | 0.480 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2020 | 856 | 0.480 |
Why?
|
| Aortic Valve Stenosis | 1 | 2019 | 345 | 0.480 |
Why?
|
| Pulmonary Artery | 2 | 2015 | 520 | 0.470 |
Why?
|
| Vascular Resistance | 1 | 2015 | 210 | 0.470 |
Why?
|
| Incidence | 14 | 2021 | 5814 | 0.470 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2018 | 260 | 0.470 |
Why?
|
| Adipokines | 1 | 2014 | 96 | 0.470 |
Why?
|
| Blood Glucose | 8 | 2017 | 1254 | 0.460 |
Why?
|
| Cystatin C | 6 | 2022 | 54 | 0.460 |
Why?
|
| Models, Biological | 2 | 2021 | 3187 | 0.460 |
Why?
|
| Catheters | 1 | 2015 | 133 | 0.460 |
Why?
|
| Healthcare Disparities | 4 | 2023 | 657 | 0.460 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2014 | 1301 | 0.450 |
Why?
|
| Uric Acid | 2 | 2017 | 116 | 0.440 |
Why?
|
| Aldosterone | 1 | 2013 | 78 | 0.440 |
Why?
|
| Sexual Dysfunctions, Psychological | 2 | 2012 | 69 | 0.440 |
Why?
|
| Logistic Models | 10 | 2021 | 3423 | 0.430 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2015 | 247 | 0.420 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2013 | 101 | 0.420 |
Why?
|
| Chronic Kidney Disease-Mineral and Bone Disorder | 2 | 2009 | 12 | 0.420 |
Why?
|
| Alkaline Phosphatase | 1 | 2013 | 213 | 0.420 |
Why?
|
| Immunosuppressive Agents | 3 | 2008 | 1436 | 0.420 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2018 | 6255 | 0.420 |
Why?
|
| Hemoglobins | 4 | 2014 | 480 | 0.410 |
Why?
|
| Insulin | 3 | 2017 | 1423 | 0.400 |
Why?
|
| Prosthesis-Related Infections | 1 | 2014 | 234 | 0.390 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2009 | 58 | 0.380 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2015 | 501 | 0.380 |
Why?
|
| Survival Rate | 10 | 2021 | 12528 | 0.380 |
Why?
|
| Motor Activity | 2 | 2014 | 709 | 0.370 |
Why?
|
| Evidence-Based Medicine | 5 | 2010 | 1027 | 0.370 |
Why?
|
| Parathyroid Hormone | 4 | 2014 | 183 | 0.370 |
Why?
|
| Meta-Analysis as Topic | 2 | 2010 | 271 | 0.360 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2011 | 82 | 0.360 |
Why?
|
| Exercise | 5 | 2022 | 1216 | 0.360 |
Why?
|
| Diuretics | 3 | 2022 | 170 | 0.350 |
Why?
|
| Catheters, Indwelling | 3 | 2008 | 382 | 0.350 |
Why?
|
| Lypressin | 1 | 2010 | 14 | 0.350 |
Why?
|
| Dyslipidemias | 2 | 2013 | 241 | 0.350 |
Why?
|
| Mycophenolic Acid | 2 | 2008 | 153 | 0.350 |
Why?
|
| Minority Groups | 2 | 2010 | 325 | 0.350 |
Why?
|
| Physicians, Family | 1 | 2010 | 55 | 0.350 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2016 | 1064 | 0.340 |
Why?
|
| Primary Health Care | 4 | 2022 | 834 | 0.340 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 123 | 0.340 |
Why?
|
| Lanthanum | 1 | 2009 | 7 | 0.340 |
Why?
|
| Adipose Tissue | 1 | 2014 | 703 | 0.340 |
Why?
|
| Hepatorenal Syndrome | 1 | 2010 | 27 | 0.340 |
Why?
|
| Hospitals, Community | 2 | 2007 | 76 | 0.330 |
Why?
|
| Prospective Studies | 18 | 2024 | 13407 | 0.320 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2009 | 41 | 0.320 |
Why?
|
| Potassium | 2 | 2023 | 327 | 0.320 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2010 | 212 | 0.310 |
Why?
|
| Veterans Health | 2 | 2021 | 173 | 0.310 |
Why?
|
| Gastric Bypass | 3 | 2017 | 93 | 0.310 |
Why?
|
| Sodium Bicarbonate | 1 | 2008 | 55 | 0.310 |
Why?
|
| Propensity Score | 5 | 2018 | 772 | 0.310 |
Why?
|
| Hypolipidemic Agents | 3 | 2014 | 187 | 0.310 |
Why?
|
| Anticholesteremic Agents | 1 | 2011 | 250 | 0.310 |
Why?
|
| Multivariate Analysis | 7 | 2016 | 4315 | 0.300 |
Why?
|
| Quality of Life | 8 | 2022 | 4808 | 0.300 |
Why?
|
| Biomedical Research | 1 | 2015 | 799 | 0.300 |
Why?
|
| Folic Acid | 3 | 2016 | 370 | 0.290 |
Why?
|
| Decision Making | 1 | 2015 | 1249 | 0.290 |
Why?
|
| Cocaine-Related Disorders | 2 | 2007 | 238 | 0.290 |
Why?
|
| Mediastinal Emphysema | 1 | 2007 | 14 | 0.290 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2021 | 7921 | 0.290 |
Why?
|
| Practice Guidelines as Topic | 5 | 2021 | 2395 | 0.290 |
Why?
|
| Lupus Nephritis | 1 | 2008 | 56 | 0.290 |
Why?
|
| Health Services Accessibility | 4 | 2015 | 819 | 0.290 |
Why?
|
| Attitude to Health | 2 | 2008 | 434 | 0.280 |
Why?
|
| Blood Pressure Determination | 2 | 2018 | 113 | 0.280 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2008 | 101 | 0.280 |
Why?
|
| Young Adult | 18 | 2020 | 22241 | 0.280 |
Why?
|
| Glucose | 4 | 2023 | 1213 | 0.280 |
Why?
|
| Naphthyridines | 2 | 2024 | 44 | 0.280 |
Why?
|
| Lipids | 5 | 2020 | 656 | 0.270 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2024 | 77 | 0.270 |
Why?
|
| Magnesium Deficiency | 1 | 2006 | 21 | 0.270 |
Why?
|
| Chest Pain | 1 | 2007 | 173 | 0.270 |
Why?
|
| Disease Transmission, Infectious | 1 | 2007 | 97 | 0.260 |
Why?
|
| Dietary Supplements | 4 | 2017 | 550 | 0.260 |
Why?
|
| Sex Factors | 5 | 2016 | 2180 | 0.260 |
Why?
|
| Waist Circumference | 3 | 2019 | 100 | 0.260 |
Why?
|
| Postoperative Complications | 3 | 2020 | 5675 | 0.250 |
Why?
|
| Vitamin B Complex | 2 | 2016 | 52 | 0.250 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2006 | 86 | 0.250 |
Why?
|
| Pneumococcal Vaccines | 1 | 2007 | 184 | 0.250 |
Why?
|
| Clinical Trials as Topic | 6 | 2018 | 3840 | 0.250 |
Why?
|
| Erythropoietin | 4 | 2014 | 224 | 0.250 |
Why?
|
| Calcium | 4 | 2014 | 1569 | 0.250 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 4 | 2009 | 24 | 0.250 |
Why?
|
| Intracranial Aneurysm | 1 | 2006 | 130 | 0.250 |
Why?
|
| Medication Systems, Hospital | 1 | 2005 | 42 | 0.240 |
Why?
|
| Lung | 1 | 2016 | 3287 | 0.240 |
Why?
|
| Carotid Stenosis | 1 | 2006 | 160 | 0.240 |
Why?
|
| Physician's Role | 1 | 2007 | 228 | 0.240 |
Why?
|
| Delivery of Health Care | 4 | 2018 | 849 | 0.240 |
Why?
|
| Catheterization, Central Venous | 1 | 2008 | 363 | 0.240 |
Why?
|
| Thrombosis | 2 | 2008 | 742 | 0.240 |
Why?
|
| Hyperhomocysteinemia | 2 | 2016 | 41 | 0.240 |
Why?
|
| Endothelin Receptor Antagonists | 1 | 2024 | 26 | 0.240 |
Why?
|
| Tacrolimus | 1 | 2006 | 347 | 0.230 |
Why?
|
| Pneumococcal Infections | 1 | 2007 | 300 | 0.230 |
Why?
|
| Medicare | 2 | 2021 | 924 | 0.230 |
Why?
|
| Arterial Pressure | 2 | 2015 | 106 | 0.230 |
Why?
|
| Influenza, Human | 2 | 2011 | 761 | 0.230 |
Why?
|
| Pericardial Effusion | 1 | 2005 | 124 | 0.230 |
Why?
|
| Systole | 2 | 2018 | 217 | 0.230 |
Why?
|
| Sarcoidosis | 1 | 2005 | 112 | 0.230 |
Why?
|
| Body Composition | 3 | 2016 | 600 | 0.220 |
Why?
|
| Hypercholesterolemia | 1 | 2006 | 264 | 0.220 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 663 | 0.220 |
Why?
|
| Length of Stay | 3 | 2015 | 1995 | 0.220 |
Why?
|
| Leptin | 3 | 2015 | 302 | 0.210 |
Why?
|
| Education, Medical, Continuing | 1 | 2005 | 230 | 0.210 |
Why?
|
| Pleural Effusion | 1 | 2005 | 228 | 0.210 |
Why?
|
| Prescriptions | 1 | 2023 | 60 | 0.210 |
Why?
|
| Medication Errors | 1 | 2005 | 189 | 0.210 |
Why?
|
| Japan | 1 | 2023 | 240 | 0.210 |
Why?
|
| Patient Education as Topic | 3 | 2017 | 745 | 0.210 |
Why?
|
| Hematinics | 3 | 2014 | 108 | 0.210 |
Why?
|
| Muscles | 1 | 2023 | 443 | 0.210 |
Why?
|
| Liver Cirrhosis | 1 | 2010 | 1048 | 0.200 |
Why?
|
| Gastrectomy | 2 | 2017 | 476 | 0.200 |
Why?
|
| Patient Outcome Assessment | 1 | 2023 | 245 | 0.200 |
Why?
|
| Cross Infection | 1 | 2007 | 547 | 0.200 |
Why?
|
| Athletic Injuries | 1 | 2022 | 70 | 0.200 |
Why?
|
| Anticoagulants | 1 | 2008 | 777 | 0.200 |
Why?
|
| Sports | 1 | 2022 | 70 | 0.200 |
Why?
|
| Influenza Vaccines | 1 | 2007 | 496 | 0.200 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2021 | 14 | 0.200 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2022 | 49 | 0.190 |
Why?
|
| Education, Medical | 1 | 2006 | 344 | 0.190 |
Why?
|
| Inpatients | 1 | 2007 | 685 | 0.190 |
Why?
|
| Mathematical Concepts | 1 | 2021 | 13 | 0.190 |
Why?
|
| Potentially Inappropriate Medication List | 1 | 2021 | 13 | 0.190 |
Why?
|
| Steroids | 1 | 2023 | 372 | 0.190 |
Why?
|
| Reference Values | 2 | 2018 | 1127 | 0.190 |
Why?
|
| Metformin | 2 | 2021 | 397 | 0.190 |
Why?
|
| Dietary Approaches To Stop Hypertension | 1 | 2020 | 6 | 0.180 |
Why?
|
| Adolescent | 15 | 2021 | 32691 | 0.180 |
Why?
|
| Glucosides | 1 | 2021 | 61 | 0.180 |
Why?
|
| Diet, Mediterranean | 1 | 2020 | 13 | 0.180 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2021 | 156 | 0.180 |
Why?
|
| Databases, Factual | 4 | 2017 | 2259 | 0.180 |
Why?
|
| Myocardial Infarction | 6 | 2018 | 1155 | 0.180 |
Why?
|
| Observational Studies as Topic | 2 | 2018 | 144 | 0.180 |
Why?
|
| American Heart Association | 4 | 2024 | 287 | 0.180 |
Why?
|
| Lipocalin-2 | 1 | 2020 | 77 | 0.180 |
Why?
|
| Benzhydryl Compounds | 1 | 2021 | 83 | 0.180 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 4964 | 0.180 |
Why?
|
| Vascular Diseases | 1 | 2022 | 234 | 0.180 |
Why?
|
| Health Behavior | 2 | 2022 | 599 | 0.180 |
Why?
|
| Absorptiometry, Photon | 3 | 2015 | 233 | 0.180 |
Why?
|
| Ferritins | 1 | 2021 | 156 | 0.180 |
Why?
|
| Chemokine CXCL12 | 1 | 2020 | 131 | 0.170 |
Why?
|
| Hodgkin Disease | 1 | 2009 | 1485 | 0.170 |
Why?
|
| Disease Management | 2 | 2017 | 1092 | 0.170 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 55 | 0.170 |
Why?
|
| C-Reactive Protein | 4 | 2016 | 555 | 0.170 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 122 | 0.170 |
Why?
|
| Alkalies | 1 | 2019 | 27 | 0.170 |
Why?
|
| Health Surveys | 1 | 2021 | 395 | 0.170 |
Why?
|
| Diagnosis, Differential | 6 | 2010 | 4839 | 0.170 |
Why?
|
| Carotid Artery Diseases | 1 | 2021 | 176 | 0.170 |
Why?
|
| Survival Analysis | 5 | 2018 | 9278 | 0.160 |
Why?
|
| Hypercalcemia | 2 | 2011 | 146 | 0.160 |
Why?
|
| Community-Acquired Infections | 1 | 2021 | 286 | 0.160 |
Why?
|
| Atrial Natriuretic Factor | 2 | 2009 | 67 | 0.160 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2021 | 153 | 0.160 |
Why?
|
| Proton Pump Inhibitors | 2 | 2018 | 272 | 0.160 |
Why?
|
| Life Style | 3 | 2020 | 617 | 0.150 |
Why?
|
| beta 2-Microglobulin | 2 | 2015 | 188 | 0.150 |
Why?
|
| Histamine H2 Antagonists | 1 | 2018 | 57 | 0.150 |
Why?
|
| Benzazepines | 1 | 2019 | 116 | 0.150 |
Why?
|
| Health Status Disparities | 1 | 2021 | 321 | 0.150 |
Why?
|
| Homocysteine | 2 | 2016 | 148 | 0.150 |
Why?
|
| Regression Analysis | 3 | 2012 | 1563 | 0.150 |
Why?
|
| Clinical Studies as Topic | 1 | 2017 | 19 | 0.150 |
Why?
|
| Glucose Tolerance Test | 2 | 2015 | 210 | 0.150 |
Why?
|
| Analysis of Variance | 3 | 2011 | 2313 | 0.150 |
Why?
|
| Longitudinal Studies | 4 | 2018 | 2045 | 0.150 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2022 | 662 | 0.150 |
Why?
|
| Circadian Rhythm | 1 | 2020 | 330 | 0.150 |
Why?
|
| Living Donors | 3 | 2013 | 170 | 0.150 |
Why?
|
| Frailty | 1 | 2020 | 133 | 0.150 |
Why?
|
| Cholesterol, LDL | 3 | 2014 | 577 | 0.150 |
Why?
|
| Hospital Costs | 1 | 2019 | 244 | 0.140 |
Why?
|
| Electrocardiography | 3 | 2023 | 1144 | 0.140 |
Why?
|
| Hyperuricemia | 1 | 2017 | 47 | 0.140 |
Why?
|
| New York | 2 | 2007 | 103 | 0.140 |
Why?
|
| Whole Grains | 1 | 2016 | 1 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2017 | 1225 | 0.140 |
Why?
|
| Ambulatory Care Facilities | 2 | 2017 | 294 | 0.140 |
Why?
|
| Docosahexaenoic Acids | 1 | 2017 | 81 | 0.140 |
Why?
|
| Gout Suppressants | 1 | 2017 | 72 | 0.140 |
Why?
|
| Peritonitis | 2 | 2008 | 98 | 0.140 |
Why?
|
| Intensive Care Units | 1 | 2021 | 729 | 0.140 |
Why?
|
| Glycopeptides | 1 | 2016 | 37 | 0.140 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2016 | 29 | 0.130 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 6192 | 0.130 |
Why?
|
| Protective Factors | 1 | 2016 | 103 | 0.130 |
Why?
|
| Neuropsychological Tests | 1 | 2020 | 1145 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2018 | 7788 | 0.130 |
Why?
|
| Aortic Valve | 1 | 2019 | 445 | 0.130 |
Why?
|
| Lipocalins | 1 | 2015 | 54 | 0.130 |
Why?
|
| Graft Rejection | 5 | 2014 | 844 | 0.130 |
Why?
|
| Pneumonia | 1 | 2021 | 791 | 0.120 |
Why?
|
| Cognitive Dysfunction | 1 | 2020 | 327 | 0.120 |
Why?
|
| Lumbosacral Region | 1 | 2015 | 55 | 0.120 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2015 | 87 | 0.120 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2015 | 66 | 0.120 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2015 | 112 | 0.120 |
Why?
|
| Graft Survival | 1 | 2018 | 1076 | 0.120 |
Why?
|
| Phantoms, Imaging | 1 | 2021 | 1330 | 0.120 |
Why?
|
| Exercise Tolerance | 1 | 2015 | 106 | 0.120 |
Why?
|
| Bias | 3 | 2024 | 210 | 0.120 |
Why?
|
| Internship and Residency | 1 | 2006 | 1440 | 0.120 |
Why?
|
| Respiratory Function Tests | 1 | 2016 | 355 | 0.120 |
Why?
|
| Waiting Lists | 3 | 2012 | 267 | 0.120 |
Why?
|
| Critical Illness | 1 | 2020 | 734 | 0.120 |
Why?
|
| Osteoarthritis | 1 | 2016 | 113 | 0.120 |
Why?
|
| Drug Utilization Review | 1 | 2014 | 37 | 0.120 |
Why?
|
| Equipment Failure | 1 | 2015 | 192 | 0.120 |
Why?
|
| Research Design | 3 | 2010 | 1559 | 0.120 |
Why?
|
| Erectile Dysfunction | 3 | 2011 | 240 | 0.120 |
Why?
|
| Insurance, Health | 2 | 2013 | 261 | 0.120 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2014 | 60 | 0.120 |
Why?
|
| Cognition | 1 | 2020 | 969 | 0.110 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2014 | 23 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 2 | 2013 | 481 | 0.110 |
Why?
|
| Ultrasonography, Doppler | 1 | 2015 | 267 | 0.110 |
Why?
|
| Quality Indicators, Health Care | 1 | 2017 | 355 | 0.110 |
Why?
|
| Program Development | 1 | 2015 | 257 | 0.110 |
Why?
|
| Bone Remodeling | 1 | 2014 | 101 | 0.110 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 2 | 2010 | 21 | 0.110 |
Why?
|
| Testosterone | 3 | 2014 | 638 | 0.110 |
Why?
|
| Television | 1 | 2014 | 80 | 0.110 |
Why?
|
| Socioeconomic Factors | 3 | 2020 | 1249 | 0.110 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2013 | 4 | 0.110 |
Why?
|
| Molecular Weight | 2 | 2014 | 714 | 0.110 |
Why?
|
| Smoking Cessation | 1 | 2019 | 770 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 603 | 0.100 |
Why?
|
| Chemokines | 1 | 2014 | 285 | 0.100 |
Why?
|
| Hypoalbuminemia | 1 | 2012 | 42 | 0.100 |
Why?
|
| Bone Density Conservation Agents | 2 | 2017 | 205 | 0.100 |
Why?
|
| Prosthesis Design | 1 | 2015 | 655 | 0.100 |
Why?
|
| Zinc | 2 | 2010 | 194 | 0.100 |
Why?
|
| Prednisone | 2 | 2006 | 1034 | 0.100 |
Why?
|
| Risk Reduction Behavior | 1 | 2014 | 209 | 0.100 |
Why?
|
| Health Services | 1 | 2013 | 100 | 0.100 |
Why?
|
| Thyroid Hormones | 1 | 2013 | 112 | 0.100 |
Why?
|
| Metabolic Diseases | 1 | 2014 | 140 | 0.100 |
Why?
|
| Hyperparathyroidism | 1 | 2012 | 101 | 0.100 |
Why?
|
| Glomerulonephritis | 2 | 2010 | 109 | 0.100 |
Why?
|
| Coronary Disease | 1 | 2016 | 741 | 0.100 |
Why?
|
| Patient Selection | 3 | 2012 | 2029 | 0.100 |
Why?
|
| Motivation | 1 | 2015 | 515 | 0.100 |
Why?
|
| Anthropometry | 1 | 2012 | 260 | 0.100 |
Why?
|
| Caloric Restriction | 1 | 2012 | 88 | 0.100 |
Why?
|
| Peer Group | 1 | 2012 | 141 | 0.090 |
Why?
|
| Drug Therapy, Combination | 2 | 2024 | 2343 | 0.090 |
Why?
|
| Liver | 1 | 2021 | 3058 | 0.090 |
Why?
|
| Heart | 1 | 2017 | 1173 | 0.090 |
Why?
|
| Intention | 1 | 2012 | 113 | 0.090 |
Why?
|
| Guideline Adherence | 2 | 2018 | 625 | 0.090 |
Why?
|
| Smoking | 2 | 2021 | 2546 | 0.090 |
Why?
|
| Diet | 2 | 2016 | 1468 | 0.090 |
Why?
|
| Cardiac Volume | 1 | 2010 | 20 | 0.090 |
Why?
|
| Atrial Function | 1 | 2010 | 14 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2009 | 7055 | 0.090 |
Why?
|
| Respiration, Artificial | 1 | 2013 | 584 | 0.090 |
Why?
|
| Coronary Artery Disease | 1 | 2017 | 884 | 0.090 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2010 | 71 | 0.090 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 1467 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2020 | 6232 | 0.080 |
Why?
|
| Seasons | 1 | 2011 | 333 | 0.080 |
Why?
|
| Calcium Carbonate | 1 | 2009 | 28 | 0.080 |
Why?
|
| Texas | 1 | 2021 | 6445 | 0.080 |
Why?
|
| Depression | 1 | 2019 | 1733 | 0.080 |
Why?
|
| Iron | 1 | 2012 | 380 | 0.080 |
Why?
|
| Quality of Health Care | 1 | 2014 | 614 | 0.080 |
Why?
|
| Sex Distribution | 1 | 2010 | 496 | 0.080 |
Why?
|
| Energy Intake | 1 | 2012 | 516 | 0.080 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2011 | 213 | 0.080 |
Why?
|
| Acetates | 1 | 2009 | 118 | 0.080 |
Why?
|
| Pantoea | 1 | 2008 | 3 | 0.080 |
Why?
|
| Acute Disease | 3 | 2009 | 2491 | 0.080 |
Why?
|
| Health Care Surveys | 1 | 2010 | 415 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2008 | 878 | 0.080 |
Why?
|
| Sodium Chloride | 1 | 2008 | 159 | 0.080 |
Why?
|
| Cerebrovascular Disorders | 1 | 2009 | 154 | 0.080 |
Why?
|
| Azathioprine | 1 | 2008 | 73 | 0.080 |
Why?
|
| Survivors | 1 | 2013 | 1021 | 0.080 |
Why?
|
| Spironolactone | 2 | 2020 | 23 | 0.080 |
Why?
|
| Artificial Intelligence | 2 | 2023 | 432 | 0.070 |
Why?
|
| Heart Atria | 1 | 2010 | 345 | 0.070 |
Why?
|
| Neoplasms | 2 | 2018 | 15951 | 0.070 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2012 | 600 | 0.070 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2008 | 118 | 0.070 |
Why?
|
| Hemoglobin A | 1 | 2006 | 30 | 0.070 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2008 | 169 | 0.070 |
Why?
|
| Oligonucleotides | 1 | 2008 | 240 | 0.070 |
Why?
|
| Cyclosporine | 1 | 2008 | 293 | 0.070 |
Why?
|
| Warfarin | 1 | 2008 | 145 | 0.070 |
Why?
|
| Educational Status | 1 | 2008 | 387 | 0.070 |
Why?
|
| Dialysis | 1 | 2006 | 24 | 0.070 |
Why?
|
| Administration, Inhalation | 1 | 2007 | 299 | 0.070 |
Why?
|
| Prodrugs | 1 | 2008 | 226 | 0.070 |
Why?
|
| Administration, Oral | 2 | 2010 | 1592 | 0.070 |
Why?
|
| Aging | 1 | 2014 | 1531 | 0.070 |
Why?
|
| Magnesium | 1 | 2006 | 170 | 0.060 |
Why?
|
| Rituximab | 2 | 2008 | 1594 | 0.060 |
Why?
|
| Diabetic Angiopathies | 1 | 2006 | 75 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 1436 | 0.060 |
Why?
|
| Endarterectomy, Carotid | 1 | 2006 | 99 | 0.060 |
Why?
|
| Morbidity | 1 | 2007 | 397 | 0.060 |
Why?
|
| Heparin | 1 | 2008 | 343 | 0.060 |
Why?
|
| Rhabdomyolysis | 1 | 2006 | 50 | 0.060 |
Why?
|
| Quality Improvement | 1 | 2012 | 912 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 2 | 2008 | 4470 | 0.060 |
Why?
|
| Catheter Ablation | 1 | 2010 | 574 | 0.060 |
Why?
|
| Injections, Intravenous | 2 | 2018 | 590 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 14639 | 0.060 |
Why?
|
| Vasoconstrictor Agents | 1 | 2006 | 165 | 0.060 |
Why?
|
| Hospital Information Systems | 1 | 2005 | 47 | 0.060 |
Why?
|
| Eosinophils | 1 | 2006 | 166 | 0.060 |
Why?
|
| Cardio-Renal Syndrome | 1 | 2024 | 6 | 0.060 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2007 | 326 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2023 | 2570 | 0.060 |
Why?
|
| Surveys and Questionnaires | 3 | 2012 | 5918 | 0.060 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2006 | 214 | 0.060 |
Why?
|
| Cocaine | 1 | 2006 | 243 | 0.060 |
Why?
|
| Electric Impedance | 2 | 2014 | 101 | 0.060 |
Why?
|
| Peritoneal Dialysis | 1 | 2006 | 140 | 0.060 |
Why?
|
| Data Collection | 1 | 2006 | 601 | 0.060 |
Why?
|
| Catheterization | 1 | 2006 | 416 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2010 | 2855 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2008 | 724 | 0.050 |
Why?
|
| Thiazides | 1 | 2022 | 5 | 0.050 |
Why?
|
| Chlorthalidone | 1 | 2022 | 24 | 0.050 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2022 | 35 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2008 | 871 | 0.050 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2022 | 31 | 0.050 |
Why?
|
| Diabetes Complications | 2 | 2017 | 309 | 0.050 |
Why?
|
| Athletes | 1 | 2022 | 60 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2006 | 610 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2005 | 453 | 0.050 |
Why?
|
| Macrolides | 1 | 2021 | 65 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2021 | 62 | 0.050 |
Why?
|
| Canrenone | 1 | 2020 | 1 | 0.050 |
Why?
|
| Global Burden of Disease | 1 | 2021 | 30 | 0.050 |
Why?
|
| Inappropriate Prescribing | 1 | 2021 | 54 | 0.050 |
Why?
|
| Interleukin-6 | 2 | 2016 | 1032 | 0.050 |
Why?
|
| Embolization, Therapeutic | 1 | 2006 | 605 | 0.050 |
Why?
|
| Cephalosporins | 1 | 2021 | 173 | 0.050 |
Why?
|
| Cardiotonic Agents | 1 | 2022 | 153 | 0.050 |
Why?
|
| Calcium Channel Blockers | 1 | 2020 | 145 | 0.040 |
Why?
|
| Linear Models | 2 | 2014 | 1092 | 0.040 |
Why?
|
| Stents | 1 | 2006 | 1000 | 0.040 |
Why?
|
| Venous Thrombosis | 2 | 2016 | 380 | 0.040 |
Why?
|
| Hospitals, Veterans | 1 | 2021 | 370 | 0.040 |
Why?
|
| Vancomycin | 1 | 2021 | 292 | 0.040 |
Why?
|
| Animals | 1 | 2024 | 61350 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2023 | 677 | 0.040 |
Why?
|
| Urinalysis | 1 | 2019 | 84 | 0.040 |
Why?
|
| Injections, Intra-Arterial | 1 | 2018 | 54 | 0.040 |
Why?
|
| Combined Modality Therapy | 3 | 2017 | 9054 | 0.040 |
Why?
|
| Health Facilities | 1 | 2018 | 73 | 0.040 |
Why?
|
| Biopsy | 1 | 2006 | 3490 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2006 | 2440 | 0.040 |
Why?
|
| Hydroxyzine | 1 | 2017 | 2 | 0.040 |
Why?
|
| Metolazone | 1 | 2017 | 5 | 0.040 |
Why?
|
| Venlafaxine Hydrochloride | 1 | 2017 | 22 | 0.040 |
Why?
|
| Body Height | 1 | 2019 | 233 | 0.040 |
Why?
|
| Histamine H1 Antagonists | 1 | 2017 | 25 | 0.040 |
Why?
|
| Furosemide | 1 | 2017 | 42 | 0.040 |
Why?
|
| Fluoxetine | 1 | 2017 | 46 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 5157 | 0.040 |
Why?
|
| Citalopram | 1 | 2017 | 34 | 0.040 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2017 | 62 | 0.040 |
Why?
|
| Markov Chains | 1 | 2018 | 188 | 0.040 |
Why?
|
| Amiodarone | 1 | 2017 | 51 | 0.040 |
Why?
|
| Causality | 1 | 2017 | 173 | 0.030 |
Why?
|
| Vitamin B 6 | 1 | 2016 | 19 | 0.030 |
Why?
|
| Recurrence | 1 | 2005 | 4878 | 0.030 |
Why?
|
| Vitamin B 12 | 1 | 2016 | 76 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2018 | 335 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2018 | 536 | 0.030 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2017 | 235 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 2014 | 2986 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 878 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2018 | 708 | 0.030 |
Why?
|
| Calcification, Physiologic | 1 | 2014 | 55 | 0.030 |
Why?
|
| Darbepoetin alfa | 1 | 2014 | 25 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2016 | 395 | 0.030 |
Why?
|
| Hypophosphatemia | 1 | 2014 | 28 | 0.030 |
Why?
|
| Epoetin Alfa | 1 | 2014 | 27 | 0.030 |
Why?
|
| Recreation | 1 | 2014 | 23 | 0.030 |
Why?
|
| Heart Rate | 1 | 2017 | 743 | 0.030 |
Why?
|
| Glycemic Index | 1 | 2014 | 29 | 0.030 |
Why?
|
| Personnel Selection | 1 | 2015 | 89 | 0.030 |
Why?
|
| Elective Surgical Procedures | 1 | 2015 | 248 | 0.030 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2014 | 105 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 2 | 2021 | 3189 | 0.030 |
Why?
|
| Intra-Abdominal Fat | 1 | 2014 | 94 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2014 | 238 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2015 | 244 | 0.030 |
Why?
|
| Body Weight | 1 | 2017 | 1282 | 0.030 |
Why?
|
| Fibrinogen | 1 | 2014 | 211 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 291 | 0.030 |
Why?
|
| South America | 1 | 2012 | 43 | 0.030 |
Why?
|
| Patient Dropouts | 1 | 2012 | 84 | 0.020 |
Why?
|
| International Agencies | 1 | 2011 | 107 | 0.020 |
Why?
|
| Global Health | 1 | 2017 | 672 | 0.020 |
Why?
|
| Donor Selection | 1 | 2012 | 110 | 0.020 |
Why?
|
| Creatine Kinase | 1 | 2011 | 93 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2014 | 515 | 0.020 |
Why?
|
| Bromocriptine | 1 | 2010 | 10 | 0.020 |
Why?
|
| Zinc Compounds | 1 | 2010 | 9 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2014 | 479 | 0.020 |
Why?
|
| Follicle Stimulating Hormone, Human | 1 | 2010 | 5 | 0.020 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2010 | 9 | 0.020 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2010 | 35 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 1503 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2016 | 2412 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 657 | 0.020 |
Why?
|
| Chlorides | 1 | 2010 | 137 | 0.020 |
Why?
|
| Renin | 1 | 2010 | 98 | 0.020 |
Why?
|
| Hypogonadism | 1 | 2014 | 278 | 0.020 |
Why?
|
| Vitamin E | 1 | 2010 | 132 | 0.020 |
Why?
|
| Europe | 1 | 2012 | 649 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2014 | 652 | 0.020 |
Why?
|
| Vitamins | 1 | 2010 | 147 | 0.020 |
Why?
|
| Luteinizing Hormone | 1 | 2010 | 165 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2012 | 602 | 0.020 |
Why?
|
| Reading | 1 | 2010 | 86 | 0.020 |
Why?
|
| Comprehension | 1 | 2010 | 104 | 0.020 |
Why?
|
| Amikacin | 1 | 2008 | 37 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2014 | 1105 | 0.020 |
Why?
|
| Nephrectomy | 1 | 2013 | 792 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2014 | 1571 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2010 | 666 | 0.020 |
Why?
|
| Ceftazidime | 1 | 2008 | 66 | 0.020 |
Why?
|
| Phenotype | 1 | 2019 | 6503 | 0.020 |
Why?
|
| Heart Conduction System | 1 | 2008 | 160 | 0.020 |
Why?
|
| Hematocrit | 1 | 2006 | 149 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2010 | 819 | 0.020 |
Why?
|
| Reoperation | 1 | 2010 | 1388 | 0.020 |
Why?
|
| Vasoconstriction | 1 | 2006 | 117 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2008 | 448 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 2008 | 424 | 0.010 |
Why?
|
| Dyspnea | 1 | 2007 | 420 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2010 | 1932 | 0.010 |
Why?
|
| Child | 2 | 2014 | 30563 | 0.010 |
Why?
|
| Risk | 1 | 2007 | 1929 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2006 | 465 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 5053 | 0.010 |
Why?
|